Value
10.0/10data confidence 20%| Component | Sub-score |
|---|---|
| EV/EBITDA | 10.0 |
- ▸Attractively valued
AVTX · Why this verdict
Why Avalo Therapeutics (AVTX) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Avalo Therapeutics is a single-pipeline biotech down 71% from its high, in a confirmed downtrend with heavy insider selling and 21% short interest, so any recovery rests on abdakibart (AVTX-009) execution.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Value rests on one pipeline asset, abdakibart (AVTX-009), made by a single contract manufacturer, so an adverse trial or supply event would hit the whole company. Bear case | Pipeline milestones for abdakibart are met without supply interruption over the next 12 months. | ↓Deteriorating |
| CounterThree HIGH concentration risks mean a single trial setback or manufacturing failure could be existential. | ||
The company is cash-burning, with free cash flow at -39,442% of revenue, no competitive moat and a quality score of 1.8. Quality breakdown | Cash burn stays covered by financing through the next data readout. | →Stable |
| CounterBurn this large relative to revenue forces dilutive raises, and a market cap of $372M leaves little room. | ||
Price is in a confirmed downtrend, below the 200-day average with a -3.8% 30-day slope, and at capitulation levels with RSI 14 and falling on-balance volume. Momentum breakdown | Selling exhausts and price stabilizes above the $6.44 stop. | ↓Deteriorating |
| CounterA death cross with distribution volume typically extends declines, and oversold bounces fail in downtrends. | ||
Insiders made 10 sales worth about $1.95M (0.525% of market cap) in 90 days with no purchases, a bearish signal. Insider | Insider selling slows and buying appears if management sees value. | ↓Deteriorating |
| CounterSales may be pre-planned or tax-related, and institutions are still accumulating. | ||
The raw analyst target of $38.50 was rejected as implausible, so upside rests on a $15.67 resistance level that is 126.1% above the $6.93 price, with 21% short interest and a put/call ratio of 7.5. Targets | Price rebounds toward the resistance level as the oversold condition resolves. | ↑Improving |
| CounterHeavy put positioning and 21% short interest suggest informed bearishness, and resistance is far above the price. | ||
Value rests on one pipeline asset, abdakibart (AVTX-009), made by a single contract manufacturer, so an adverse trial or supply event would hit the whole company.
↓DeterioratingBear case
- Expectation
- Pipeline milestones for abdakibart are met without supply interruption over the next 12 months.
CounterThree HIGH concentration risks mean a single trial setback or manufacturing failure could be existential.
The company is cash-burning, with free cash flow at -39,442% of revenue, no competitive moat and a quality score of 1.8.
→StableQuality breakdown
- Expectation
- Cash burn stays covered by financing through the next data readout.
CounterBurn this large relative to revenue forces dilutive raises, and a market cap of $372M leaves little room.
Price is in a confirmed downtrend, below the 200-day average with a -3.8% 30-day slope, and at capitulation levels with RSI 14 and falling on-balance volume.
↓DeterioratingMomentum breakdown
- Expectation
- Selling exhausts and price stabilizes above the $6.44 stop.
CounterA death cross with distribution volume typically extends declines, and oversold bounces fail in downtrends.
Insiders made 10 sales worth about $1.95M (0.525% of market cap) in 90 days with no purchases, a bearish signal.
↓DeterioratingInsider
- Expectation
- Insider selling slows and buying appears if management sees value.
CounterSales may be pre-planned or tax-related, and institutions are still accumulating.
The raw analyst target of $38.50 was rejected as implausible, so upside rests on a $15.67 resistance level that is 126.1% above the $6.93 price, with 21% short interest and a put/call ratio of 7.5.
↑ImprovingTargets
- Expectation
- Price rebounds toward the resistance level as the oversold condition resolves.
CounterHeavy put positioning and 21% short interest suggest informed bearishness, and resistance is far above the price.
Per-dimension breakdown
Quality
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -39442% of revenue
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
1.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 1.0 |
| Volume | 2.0 |
- ▸Capitulation risk (RSI 18, below 200MA)
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -4.5%/30d — confirmed downtrend
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| news sentiment | 2.4 |
| Analyst rating | 8.2 |
| Price target | 10.0 |
- ▸Negative news sentiment (-0.52)
- ▸Light analyst coverage (10.0) — signal dampened
- ▸Analyst upside: 414%
Insider
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Heavy insider selling — $1,931,486 (0.506% of mkt cap)
- ▸Institutions accumulating
Peer rank
6.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 4.5 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.8 |
| support resistance | 9.3 |
| 52w position | 0.0 |
| gap | 6.0 |
Risk (lower is worse)
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.3 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| beta | 8.8 |
| debt equity | 10.0 |
| news risk | 3.0 |
- ▸High short interest justified: 22%
- ▸Elevated put/call: 4.56
- ▸High IV: 207%
- ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 3.9 |
| news activity | 8.0 |
- ▸Earnings concerns: 2B/2M
- ▸Earnings in 13 days
How the verdict was assembled
Engine trigger
Market cap $382M below $400M minimum. Not in investable universe.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:MARKET_CAPPassed (3)
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (3)
- MOMENTUM:1.4<4.5
- INSIDER:0.51%=EXTREME
- DEATH_CROSS:HARD_BLOCK
Warning (3)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
- EARNINGS_PROXIMITY:13d<=14d (soft)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
SetupFalling Knife — Death cross, below all MAs, RSI 18, MACD bearish
EdgeInst Constrain — Small cap ($0.4B) below institutional reach
SuitabilitySpeculative — Drawdown -71% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The HOLD_IF_HOLDING verdict reflects the MOMENTUM gate's 1.4<4.5 outcome against Value at 10.0 and asymmetric R:R of 0.00.
The strongest dimensions are Value at 10.0, Sentiment at 7.2, and Peer rank at 6.1; the weakest are Momentum at 1.4, Quality at 1.8, and Risk (lower is worse) at 2.9. The V9 engine flagged 3 failed gates with 3 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Asset Pipeline Risk
Trip ifAny pipeline delay exceeds 6 months for abdakibart (AVTX-009) milestones.
- P2Deep Cash Burn
Trip ifFree cash flow falls below -50,000% of revenue from the current -39,442%.
- P3Confirmed Downtrend Capitulation
Trip ifPrice falls below the $6.44 stop level from the current $6.93.
- P4Heavy Insider Selling
Trip ifInsider selling exceeds $3M in a trailing 90 days from the current $1.95M.
- P5Technical Upside No Analyst Target
Trip ifPut/call ratio stays above 5 from the current 7.5 while short interest exceeds 21%.